Search results
Results from the WOW.Com Content Network
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...
In May 2019, the FDA approved two tafamidis preparations for the treatment of transthyretin-mediated cardiomyopathy, but has not approved it for the treatment of transthyretin familial amyloid polyneuropathy. [15] In August 2018, the FDA approved patisiran, an siRNA-based treatment, at an expected cost of up to $450,000 per year. [16]
After a split vote by a Food and Drug Administration advisory panel, the agency will have the final say on whether Pfizer's (NYS: PFE) tafamidis meglumine is approved in the U.S. The decision won ...
"Mirdametinib (Code C52195)". NCI Thesaurus . Clinical trial number NCT03962543 for "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)" at ClinicalTrials.gov
(Reuters) -Alnylam Pharmaceuticals said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration ...
They estimate a market of 35,000 patients in the U.S. and Europe, with an additional 23,000 in some countries in the Middle East where Casgevy is also approved.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
$5.36 billion (37%) Source: Pfizer. Note: Analyst consensus estimates for the quarter provided by FactSet. N/M = Change figures are not meaningful due to a one-time, non-cash revenue reversal of ...